{
"info": {
"nct_id": "NCT05184257",
"official_title": "The Effectiveness of Zoladex® 10.8 mg Compared to Zoladex® 3.6mg in the Treatment of Premenopausal and Perimenopausal Hormone Receptor Positive Breast Cancer: A Real-World Study",
"inclusion_criteria": "Healthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "",
"miscellaneous_criteria": "Inclusion Criteria\n\n* Diagnosed with primary breast cancer\n* Female, ≥18 years old (at index date)\n* HR positive\n* Receive Zoladex® 10.8 mg or Zoladex® 3.6 mg treatment\n* Premenopausal status prior to the treatment of Zoladex®. Baseline premenopausal status will be confirmed if the patient's last E2 measurement within 180 days prior to the index date indicated premenopausal status or there was a recorded menstrual history within 180 days prior to the index date\n* At least one actual or expected E2 testing measurement within 8-28 weeks of the index date Exclusion Criteria\n* Patients received concurrent treatments that may affect E2 testing results"
},
"inclusion_lines": [
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be FEMALE",
"criterions": [
{
"exact_snippets": "Must be FEMALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "female"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [],
"miscellaneous_lines": [
{
"line": "* Diagnosed with primary breast cancer",
"criterions": [
{
"exact_snippets": "Diagnosed with primary breast cancer",
"criterion": "primary breast cancer",
"requirements": [
{
"requirement_type": "diagnosis",
"expected_value": true
}
]
}
]
},
{
"line": "* Female, ≥18 years old (at index date)",
"criterions": [
{
"exact_snippets": "Female",
"criterion": "gender",
"requirements": [
{
"requirement_type": "value",
"expected_value": "female"
}
]
},
{
"exact_snippets": "≥18 years old",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum age",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "years"
}
}
]
}
]
},
{
"line": "* HR positive",
"criterions": [
{
"exact_snippets": "HR positive",
"criterion": "hormone receptor status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "positive"
}
]
}
]
},
{
"line": "* Receive Zoladex® 10.8 mg or Zoladex® 3.6 mg treatment",
"criterions": [
{
"exact_snippets": "Receive Zoladex® 10.8 mg or Zoladex® 3.6 mg treatment",
"criterion": "Zoladex® treatment",
"requirements": [
{
"requirement_type": "dosage",
"expected_value": [
"10.8 mg",
"3.6 mg"
]
}
]
}
]
},
{
"line": "* Premenopausal status prior to the treatment of Zoladex®. Baseline premenopausal status will be confirmed if the patient's last E2 measurement within 180 days prior to the index date indicated premenopausal status or there was a recorded menstrual history within 180 days prior to the index date",
"criterions": [
{
"exact_snippets": "Premenopausal status prior to the treatment of Zoladex®",
"criterion": "premenopausal status",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "prior to the treatment of Zoladex®"
}
]
},
{
"exact_snippets": "Baseline premenopausal status will be confirmed if the patient's last E2 measurement within 180 days prior to the index date indicated premenopausal status",
"criterion": "E2 measurement",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 180 days prior to the index date"
},
{
"requirement_type": "indication",
"expected_value": "premenopausal status"
}
]
},
{
"exact_snippets": "recorded menstrual history within 180 days prior to the index date",
"criterion": "menstrual history",
"requirements": [
{
"requirement_type": "timing",
"expected_value": "within 180 days prior to the index date"
}
]
}
]
},
{
"line": "* At least one actual or expected E2 testing measurement within 8-28 weeks of the index date Exclusion Criteria",
"criterions": [
{
"exact_snippets": "At least one actual or expected E2 testing measurement within 8-28 weeks of the index date",
"criterion": "E2 testing measurement",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
},
{
"requirement_type": "timing",
"expected_value": {
"comparisons": [
{
"operator": ">=",
"value": 8,
"unit": "weeks"
},
{
"operator": "<=",
"value": 28,
"unit": "weeks"
}
]
}
}
]
}
]
},
{
"line": "* Patients received concurrent treatments that may affect E2 testing results",
"criterions": [
{
"exact_snippets": "concurrent treatments that may affect E2 testing results",
"criterion": "concurrent treatments",
"requirements": [
{
"requirement_type": "impact on E2 testing results",
"expected_value": true
}
]
}
]
}
],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": [
{
"line": "Inclusion Criteria",
"criterions": []
}
]
}